127 related articles for article (PubMed ID: 19559720)
21. Botulinum toxin-induced focal paresis in mice is unaffected by muscle activity.
Kutschenko A; Reinert MC; Klinker F; Paulus W; Hesse S; Liebetanz D
Muscle Nerve; 2011 Dec; 44(6):930-6. PubMed ID: 22102464
[TBL] [Abstract][Full Text] [Related]
22. The in vivo rat muscle force model is a reliable and clinically relevant test of consistency among botulinum toxin preparations.
Pickett A; O'Keeffe R; Judge A; Dodd S
Toxicon; 2008 Sep; 52(3):455-64. PubMed ID: 18639570
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX) in healthy volunteers.
Jost WH; Kohl A; Brinkmann S; Comes G
J Neural Transm (Vienna); 2005 Jul; 112(7):905-13. PubMed ID: 15526142
[TBL] [Abstract][Full Text] [Related]
24. The effects of botulinum toxin A on muscle histology during distraction osteogenesis.
Olabisi R; Chamberlain CS; Petr S; Steiner S; Consigny D; Best TM; Vanderby R; Schultz E; Noonan KJ
J Orthop Res; 2009 Mar; 27(3):310-7. PubMed ID: 18752291
[TBL] [Abstract][Full Text] [Related]
25. A pharmacodynamic comparison study of different botulinum toxin type A preparations.
Kim SB; Ban B; Jung KS; Yang GH
Dermatol Surg; 2013 Jan; 39(1 Pt 2):150-4. PubMed ID: 23301818
[TBL] [Abstract][Full Text] [Related]
26. Botulinum toxin-induced paralysis leads to slower myosin heavy chain isoform composition and reduced titin content in juvenile rat gastrocnemius muscle.
Legerlotz K; Matthews KG; McMahon CD; Smith HK
Muscle Nerve; 2009 Apr; 39(4):472-9. PubMed ID: 19260067
[TBL] [Abstract][Full Text] [Related]
27. [The effect of tripterygium wilfordii polyglycosidium on the compound action potential of skeletal muscle in experimental animals with myasthenia gravis].
Wang T; Zhang Y; Lü GN; Li KY; Xu JG
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 May; 35(3):379-81. PubMed ID: 15181842
[TBL] [Abstract][Full Text] [Related]
28. Induction of acute lung injury after intranasal administration of toxin botulinum a complex.
Taysse L; Daulon S; Calvet J; Delamanche S; Hilaire D; Bellier B; Breton P
Toxicol Pathol; 2005; 33(3):336-42. PubMed ID: 15814363
[TBL] [Abstract][Full Text] [Related]
29. Experimental conditions substantially influence botulinum toxin potency testing.
Mander G; Fink K; Vey M
Clin Neuropharmacol; 2009; 32(4):234; author reply 235. PubMed ID: 19644233
[No Abstract] [Full Text] [Related]
30. Comparison between botulinum neurotoxin type A2 and type A1 by electrophysiological study in healthy individuals.
Mukai Y; Shimatani Y; Sako W; Asanuma K; Nodera H; Sakamoto T; Izumi Y; Kohda T; Kozaki S; Kaji R
Toxicon; 2014 Apr; 81():32-6. PubMed ID: 24495439
[TBL] [Abstract][Full Text] [Related]
31. Botulinum toxin injections as a method for chemically denervating skeletal muscle to test functional hypotheses: a pilot study in Lepomis cyanellus.
O'Neill MW; Gibb AC
Physiol Biochem Zool; 2007; 80(2):241-9. PubMed ID: 17252520
[TBL] [Abstract][Full Text] [Related]
32. Reduced potency after refrigerated storage of botulitum toxin A: human extensor digitorum brevis muscle study.
Paik NJ; Seo K; Eun HC
Mov Disord; 2006 Oct; 21(10):1759-63. PubMed ID: 16856132
[TBL] [Abstract][Full Text] [Related]
33. Botulinum type A toxin neutralisation by specific IgG and its fragments: a comparison of mouse systemic toxicity and local flaccid paralysis assays.
Jones RG; Alsop TA; Hull R; Tierney R; Rigsby P; Holley J; Sesardic D
Toxicon; 2006 Sep; 48(3):246-54. PubMed ID: 16870221
[TBL] [Abstract][Full Text] [Related]
34. Botulinum toxin type A inhibits rat pyloric myoelectrical activity and substance P release in vivo.
Hou YP; Zhang YP; Song YF; Zhu CM; Wang YC; Xie GL
Can J Physiol Pharmacol; 2007 Feb; 85(2):209-14. PubMed ID: 17487262
[TBL] [Abstract][Full Text] [Related]
35. Improved calcium utilization at motor nerve terminals exposed to botulinum neurotoxin in mice.
Fujikawa R; Ishii T; Komori S; Nishimura M
J Physiol Sci; 2008 Dec; 58(6):419-24. PubMed ID: 18845060
[TBL] [Abstract][Full Text] [Related]
36. Urodynamic and immunohistochemical evaluation of intravesical botulinum toxin A delivery using liposomes.
Chuang YC; Tyagi P; Huang CC; Yoshimura N; Wu M; Kaufman J; Chancellor MB
J Urol; 2009 Aug; 182(2):786-92. PubMed ID: 19539320
[TBL] [Abstract][Full Text] [Related]
37. Muscle biopsy substantiates long-term MRI alterations one year after a single dose of botulinum toxin injected into the lateral gastrocnemius muscle of healthy volunteers.
Schroeder AS; Ertl-Wagner B; Britsch S; Schröder JM; Nikolin S; Weis J; Müller-Felber W; Koerte I; Stehr M; Berweck S; Borggraefe I; Heinen F
Mov Disord; 2009 Jul; 24(10):1494-503. PubMed ID: 19489066
[TBL] [Abstract][Full Text] [Related]
38. Enhanced Effect of Botulinum Toxin A Injections into the Extensor Digitorum Brevis Muscle after Local Mechanical Leg Vibration: A Case Report.
Hefter H; Beek J; Rosenthal D; Samadzadeh S
Toxins (Basel); 2021 Jun; 13(6):. PubMed ID: 34203875
[TBL] [Abstract][Full Text] [Related]
39. Effects of purification on the bioavailability of botulinum neurotoxin type A.
Cheng LW; Onisko B; Johnson EA; Reader JR; Griffey SM; Larson AE; Tepp WH; Stanker LH; Brandon DL; Carter JM
Toxicology; 2008 Jul; 249(2-3):123-9. PubMed ID: 18538461
[TBL] [Abstract][Full Text] [Related]
40. Localized tetanus in immunized mice.
Fishman PS; Parks DA; Bowen T; Matthews CC
Neurotoxicology; 2009 Jul; 30(4):697-701. PubMed ID: 19465055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
